Hartmann et al. further identified that CXCR4-driven adhesion enhances chemotherapy resistance in SCLC by activating integrin signaling, suggesting that CXCR4 inhibition could prevent tumor-stroma interactions that contribute to residual disease and relapses (Hartmann et al., 2005). This evidence concerns the gene CXCR4 and small cell lung carcinoma.